Biogen (BIIB) Stock Forecast & Price Target

$156.00 +0.57 (+0.37%)

(As of 11/20/2024 ET)

Biogen - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 28 Analyst Ratings

Sell
0

Hold
13

Buy
15

Based on 28 Wall Street analysts who have issued ratings for Biogen in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 28 analysts, 13 have given a hold rating, and 15 have given a buy rating for BIIB.

Consensus Price Target

$258.96
66.00% Upside

According to the 28 analysts' twelve-month price targets for Biogen, the average price target is $258.96. The highest price target for BIIB is $342.00, while the lowest price target for BIIB is $180.00. The average price target represents a forecasted upside of 66.00% from the current price of $156.00.

Get the Latest News and Ratings for BIIB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Biogen and its competitors.

BIIB Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	15 Buy rating(s)	16 Buy rating(s)	17 Buy rating(s)	20 Buy rating(s)
Hold	13 Hold rating(s)	9 Hold rating(s)	8 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$258.96	$271.39	$276.35	$326.08
Forecasted Upside	66.00% Upside	45.99% Upside	34.80% Upside	41.01% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

When it comes to NVDA… “acceleration cycles” are the key (Ad)

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

BIIB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BIIB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Biogen Stock vs. The Competition

Type	Biogen	Medical Companies	S&P 500
Consensus Rating Score	2.54	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	66.00% Upside	26,931.55% Upside	9.81% Upside
News Sentiment Rating	Positive News See Recent BIIB News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/18/2024	Needham & Company LLC 2 of 5 stars	A. Fadia Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$270.00 ➝ $270.00	+68.76%
11/15/2024	Wolfe Research 3 of 5 stars	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
11/15/2024	Robert W. Baird 2 of 5 stars		Boost Target	Outperform ➝ Outperform	$294.00 ➝ $300.00	+81.94%
11/14/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$190.00	+14.60%
11/4/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$220.00 ➝ $210.00	+22.40%
10/31/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$190.00 ➝ $180.00	+2.18%
Get the Latest News and Ratings for BIIB and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.
10/31/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$270.00 ➝ $255.00	+44.75%
10/31/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$300.00 ➝ $275.00	+56.24%
10/31/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$300.00 ➝ $300.00	+69.35%
10/31/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight	$285.00 ➝ $204.00	+12.60%
10/17/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$260.00 ➝ $230.00	+21.60%
10/10/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
10/4/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$292.00 ➝ $269.00	+45.47%
10/3/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Verma Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$234.00 ➝ $202.00	+9.42%
9/23/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$210.00 ➝ $205.00	+4.17%
9/9/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$292.00 ➝ $292.00	+46.34%
8/6/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$277.00 ➝ $251.00	+26.52%
8/5/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$340.00 ➝ $302.00	+50.14%
8/2/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$240.00 ➝ $225.00	+9.76%
8/2/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sector Outperform ➝ Sector Outperform	$275.00 ➝ $244.00	+18.10%
7/12/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$335.00 ➝ $313.00	+32.18%
7/3/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
5/3/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$339.00 ➝ $342.00	+57.23%
4/12/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$280.00 ➝ $260.00	+27.65%
2/20/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$310.00 ➝ $305.00	+39.35%
2/12/2024	Bank Of America (Bofa) Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$290.00 ➝ $280.00	+14.82%
1/7/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Shrader Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral
12/14/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$315.00 ➝ $287.00	+12.30%
8/8/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$282.00 ➝ $275.00	+1.39%
5/11/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$320.00 ➝ $350.00	+11.73%
5/1/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$270.00 ➝ $350.00	+15.04%
2/16/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$300.00 ➝ $315.00	+12.91%
12/1/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$370.00	+22.16%
11/30/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$325.00 ➝ $350.00	+20.11%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:16 AM ET.

Should I Buy Biogen Stock? BIIB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, November 7, 2024. Please send any questions or comments about these Biogen pros and cons to contact@marketbeat.com.

Biogen
Bull Case

Here are some ways that investors could benefit from investing in Biogen Inc.:

Biogen Inc. stock price is currently trading at $194.67, showing potential for growth based on analyst forecasts and recent trading patterns.
Biogen Inc. has a strong institutional investor base, with significant investments from reputable funds like Healthcare of Ontario Pension Plan Trust Fund and Lighthouse Investment Partners LLC.
Wall Street analysts have given Biogen Inc. positive ratings, with a consensus target price of $275.30, indicating confidence in the company's future performance.
Biogen Inc. has a diverse portfolio of biotechnology products and a history of innovation in the healthcare sector, which could lead to future breakthroughs and revenue growth.
Recent acquisitions and stake purchases by institutional investors suggest a positive outlook for Biogen Inc.'s future prospects and market position.

Biogen
Bear Case

Investors should be bearish about investing in Biogen Inc. for these reasons:

Biogen Inc. stock has experienced fluctuations in price, indicating potential volatility in the market and uncertainty surrounding the company's performance.
Analyst downgrades and target price reductions by financial institutions like Wells Fargo & Company and Barclays may signal concerns about Biogen Inc.'s growth potential and market competitiveness.
Competition in the biotechnology sector is intense, with other companies constantly innovating and introducing new products, posing a challenge to Biogen Inc.'s market share and profitability.
Regulatory challenges and changes in healthcare policies could impact Biogen Inc.'s operations and financial performance, leading to uncertainties for investors.
Market conditions and macroeconomic factors can influence the biotechnology industry, affecting Biogen Inc.'s stock price and overall investment returns.

BIIB Forecast - Frequently Asked Questions

: According to the research reports of 28 Wall Street equities research analysts, the average twelve-month stock price forecast for Biogen is $258.96, with a high forecast of $342.00 and a low forecast of $180.00.
: 28 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 13 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BIIB shares.
: According to analysts, Biogen's stock has a predicted upside of 66.00% based on their 12-month stock forecasts.
: Over the previous 90 days, Biogen's stock had 2 downgrades and 1 upgrade by analysts.
: Biogen has been rated by research analysts at Barclays, BMO Capital Markets, Cantor Fitzgerald, Citigroup, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer, Raymond James, Robert W. Baird, Royal Bank of Canada, TD Cowen, UBS Group, Wedbush, and Wolfe Research in the past 90 days.
: Analysts like Biogen less than other "medical" companies. The consensus rating score for Biogen is 2.54 while the average consensus rating score for "medical" companies is 2.80. Learn more on how BIIB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Trump said you could learn something from this man (Ad)

Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.

Here’s everything you need to know.

This page (NASDAQ:BIIB) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biogen (BIIB) Stock Forecast & Price Target